ArticleDiscover oncology2025
The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers. METHODS AND MATERIALS: A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1-2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs.
resultOf 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, p < 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), p < 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients.
conclusionAlthough upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.